PREP

Geographic shifts in the HIV epidemic, racial disparities, and the complexities of the medical system all present obstacles to prevention and treatment services.
 

Researchers, advocates, and other stakeholders are urging for care to be expanded to overcome barriers in high-risk populations to address the HIV epidemic, as part of a series published in The Lancet HIV in the USA Series.

In order to eradicate HIV, the researchers said increasing health coverage will be essential. Without that, HIV will continue to spread, and individuals will be unaware of their status.
 

Patients with HIV who were hospitalized with COVID-19 were found to have high proportions of HIV virologic control on antiretroviral therapy.

At the virtual 2020 ASHP Midyear Clinical Meeting and Exhibition, Elyse Tung, PharmD, BCACP, discussed key counseling points for pharmacists to address with patients when prescribing and managing PrEP.

Additional non-oral options could provide more manageable forms of PrEP treatment for patients, potentially increasing global uptake of PrEP in the future.

Further, the study showed cabotegravir was 89% more effective than daily oral FTC/TDF for pre-exposure prophylaxis (PrEP).

Further, the study showed cabotegravir was 89% more effective than daily oral FTC/TDF for pre-exposure prophylaxis (PrEP).

This activity is supported by an educational grant from Janssen Therapeutics, division of Janssen Products, LP.

Top news of the week from Pharmacy Times. 
 

Less than 10% of the people who should be taking pre-exposure prophylaxis for HIV are taking the medications. 

 

Insurance companies are currently investigating the option of modifying which medications they will cover for HIV pre-exposure prophylaxis (PrEP) therapy, with broad implications for patient access.